A recent FDA Warning Letter to a US veterinary drug manufacturer reveals a pattern of out-of-specification (OOS) mismanagement. Confirmed OOS results were overridden by averaging retest data, specifications were changed by hand to accommodate failures, and products were distributed regardless. Additional findings cover the use of raw materials beyond their retest dates and the absence of formal validation protocols and reports.